Category: pharmacological
Aliases: Jardiance, BI 10773
Selective SGLT2 inhibitor (SGLT2 vs SGLT1 >2700-fold selectivity) — blocks ~60% of proximal tubular glucose reabsorption, causing glucosuria 60–90 g/day. Non-insulin-dependent glucose lowering (no hypoglycaemia as monotherapy). Cardioprotective mechanism disputed — proposed osmotic diuresis, natriuresis, improved myocardial energetics (ketone shift), reduced sympathetic tone. EMPA-REG OUTCOME demonstrated MACE + all-cause mortality reduction in T2D with established CVD.
PO: 11.7h